Gastrointestinal Cancer | Topics

Patients With Frontline Gastric/GEJ Cancers Benefit When Nivolumab Is Added to Chemotherapy
September 19, 2021

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.

Patients With Esophageal Squamous Cell Carcinoma Treated With Frontline Toripalimab Plus Chemo Derive Survival Benefit
September 18, 2021

Results from the phase 3 JUPITER06 trial demonstrated positive outcomes with toripalimab plus platinum-based chemotherapy in patients with treatment-naïve advanced or metastatic esophageal squamous cell carcinoma.

Western Patients With HER2-Positive Gastric/GEJ Cancers Demonstrate Promising Responses to Trastuzumab Deruxtecan
September 18, 2021

Updated results of DESTINY-Gastric02 trial show antitumor response with trastuzumab deruxtecan in patients with in certain patients with HER2-positive gastric/gastroesophageal junction.

Patients with Advanced Esophageal Cancers Benefit From Addition of Sintilimab
September 17, 2021

Results of 2 studies presented at 2021 ESMO demonstrate superior efficacy of sintilimab plus chemotherapy versus chemotherapy alone in certain gastrointestinal cancers.

Promising Responses Observed in HER2+, Metastatic Biliary Tract Cancer Following Treatment With Pertuzumab and Trastuzumab
September 15, 2021

Patients with HER2-positive, metastatic biliary tract cancer experienced promising responses and a tolerable safety profile following treatment with pertuzumab plus trastuzumab.

NovoTTF-200T Delivery System Given a Breakthrough Designation by the FDA for Advanced Liver Cancer
September 10, 2021

The NovoTTF-200T System was given a breakthrough designation by the FDA as treatment strategy that may work in conjunction with bevacizumab and atezolizumab to treat patients with advanced liver cancer.

Certain Genomic Pathways of Gut Microbiome Significantly Associated With Survival in Nivolumab-Treated Patients With Gastric/GEJ Cancer
September 02, 2021

Data from patients with gastric or gastroesophageal junction cancers who were treated with nivolumab showed that effects in the genomic pathways of the gut microbiome may be significantly associated with survival.

FDA Approves Oncomine Dx Target Test as a Companion Diagnostic for Ivosidenib in IDH1+ Cholangiocarcinoma
August 26, 2021

Oncomine Dx Target Test is now approved by the FDA as a companion diagnostic for patients with IDH1-mutant cholangiocarcinoma who may be candidates for treatment with ivosidenib.

Sintilimab Plus Chemotherapy Meets Primary End Point of Significantly Improved OS for Advanced/Metastatic Gastric or GEJ Carcinoma
August 19, 2021

The phase ORIENT-16 trial indicated that the addition of sintilimab to chemotherapy significantly improved of overall survival compared with placebo.

Risk Prediction Model Created to Monitor 90-Day Mortality Following Esophagectomy in Esophageal Cancer
August 04, 2021

Oncologists can now use the International Esodata Study Group’s risk predictor model to identify patients with esophageal cancer who might be at a very high-risk of death following an esophagectomy.